drugset / Trial / NCT00020748

Epirubicin Plus Irinotecan in Treating Patients With Advanced Cancer

NCT00020748

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of epirubicin plus irinotecan in treating patients who have advanced cancer.

Timeline

Start
2000-08
Primary completion
2004-10
Completion
2004-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Epirubicin Small molecule Intravenous
Subject Irinotecan Small molecule Intravenous